AIM To investigate the influences of Jinkui Shenqi Pill combined with sacubitril-valsartan on TCM syndrome integral (TCMSI), mean ventricular wall stress (MWS) and serum myostatin (MSTN) levels in patients with chronic heart failure (CHF).
METHODS A total of 100 CHF patients admitted in our hospital from March 2021 to April 2022 were selected as the research subjects and they were randomly grouped into the control group (50 cases) and the observation group (50 cases). The control group was treated with sacubitril-valsartan and theobservation group was treated with Jinkui Shenqi Pill and sacubitril-valsartan. TCMSI score, MWS and serum MSTN level were compared between the two groups.
RESULTS The total effective rate of the observation group was significantly higher than that of the control group (P<0.05); Compared with before treatment, the TCMSI scores of the two groups significantly decreased after treatment, and the observation group was significantly lower than the control group (both P<0.01); After treatment, the stroke volume (SV), left ventricular ejection fraction (LVEF), and 6-minute walking test (6MWT) distance values (LVEF and 6MWT) of the two groups significantly increased, and the observation group was significantly higher than the control group (all P<0.01); Compared with before treatment, the average wall stress (MWS) and left ventricular end systolic diameter (LVESD) were decreased, left ventricular end diastolic diameter (LVEDD) and left ventricular end diastolic volume (LVEDV) were increased, and left ventricular end systolic volume (LVESV) was significantly decreased in both groups after treatment, and the difference between observation group and control group was significant (all P<0.01); Compared with before treatment, after treatment, the standard deviation between sinus beats (SDNN), root mean square (RMSDD) of normal adjacent sinus beat interval difference, percentage of adjacent sinus beat interval difference>50 ms (PNN50), and high-frequency Hertz (HF) were significantly increased in both groups, and the observation group was significantly higher than the control group (all P<0.01); Compared with before treatment, the serum MSTN levels in the two groups significantly decreased after treatment, and the observation group was significantly lower than the control group (both P<0.01).
CONCLUSION Jinkui Shenqi Pill combined with sacubitril-valsartan effectively improve the clinical symptoms of CHF patients, reduce their TCMSI scores, MWS and serum MSTN levels and improve cardiac functions and the effect is remarkable.
DownLoad: